BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Gentronix Limited Use Abcellute Ltd Preserved Hepatocytes to Enhance In Vitro Genotoxicity Testing


6/13/2008 11:16:25 AM

Cardiff, UK. June 16, 2008: Safety assessment in drug discovery requires the in vitro genotoxicity assessment of metabolites. This is currently achieved by incubating compounds with liver extracts (‘S9’), because when genotoxicity tests were developed there was no reliable supply of fresh hepatocytes. Being able to use fresh hepatocytes for testing metabolites, instead of extracts with their limited metabolic activity, could be a major advance. This possibility has now moved a significant step closer. In the first stage of a major collaboration, Gentronix have successfully co-cultured their GreenScreen HC genotoxicity reporter cells with fresh hepatocytes preserved in Abcellute’s matrix in the presence of test material.

The results were presented by Gentronix at the recent US Society of Toxicology Meeting. According to Professor Richard Walmsley of Gentronix these results promise a major breakthrough; “We are extremely encouraged by these results. Our initial work shows that the GreenScreen HC assay can be used to assess the genotoxicity of metabolites generated by either S9 extracts or non-frozen preserved primary hepatocytes provided by Abcellute Ltd. The predictable differences in metabolism provided by S9 extracts and hepatocytes are readily apparent from the results - and represent a refinement in the use of animal material. It is now conceivable that preserved human hepatocytes could be routinely used in pre-clinical safety assessment.”

Dr Nathan Griffiths, Abcellute’s Chief Scientific Officer, said: “The results indicate the potential for our matrix in this exciting area. They match similar evaluations in our core preclinical market conducted by leading pharmaceutical companies, contract research organisations and academic institutes in Europe, the USA and Japan”.

Abcellute
Founded in 2001 and based on the work of Dr Peter Evans and Dr Nathan Griffiths, Abcellute is a product led company which exploits a patent protected cell stabilising platform technology which enables the non-frozen preservation and transport of live organ-derived cells without the loss of viability or function. The Abcellute product is currently being sold to pharmaceutical companies in Europe and Japan for pre-clinical drug testing and the company is actively expanding these sales to the USA. In the long-term, the company plans to develop the preservation technology to provide products for cell-based therapeutics.

Gentronix Ltd
Founded in 1999 by Prof Richard Walmsley at the University of Manchester, Gentronix Ltd has developed technology for the accurate identification of genotoxic compounds. GreenScreen HC is a human cell-based assay for use in screening and uses a simple, rapid and high-throughput microplate protocol. It is used by companies in the USA, EC and Japan, and is also provided by some contract service organisations.

Support
This work was supported in part by a grant from the National Centre for the Replacement, Refinement and Reduction of Animals in Research UK

Corporate Inquiries
Alex B. Watson, Chief Executive Officer
Tel: +44 (0)1732840040
Email: alex.watson@abcellute.com

Media Inquiries
Richard Hayhurst, Hayhurst Media
Tel +44 (0) 7711821527 or +44 (0) 208 4873788
Email:richard@hayhurstmedia.com

For Gentronix
Professor Richard Walmsley
Tel: +44(0)161 6037662
Email:richard.walmsley@gentronix.co.uk


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->